• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies setup by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different respiratory viral infections. Atriva’s lead product ATR-002 is a first-in-class host-targeting agent, inhibiting viral replication in influenza and other respiratory infections, an area of high unmet medical need. The Company owns five broad patent families with broad coverage related to the use of MEK inhibitors for anti-viral therapies and late expiry in 2038. Atriva was a winner of the German 2016 Science4Live business plan concept contest. Atriva Therapeutics is located in Tübingen, Germany. *

 

	Start	2015-05-21 established
	Predecessor	University of Tübingen (Eberhard-Karls-Universität)
	Industry	virostatic agent
	Industry 2	ATR-002 (Atriva Therapeutics)
	Person	Lichtenberger, Rainer (Atriva 201606 CEO + Co-Founder before Cevec + Merckle/ratiopharm + Merck KGaA)
	Region	Tübingen
	Country	Germany
	Street	1 Eisenbahnstr.
	City	72072 Tübingen
	Tel	+49-7071-859-7673
		Address record changed: 2020-12-11
Basic data	Employees	n. a.
		* Document for �About Section�: Atriva Therapeutics GmbH. (1/3/19). "Press Release: Atriva Therapeutics Announces First Closing of Series A Financing Round". Tübingen.
		Record changed: 2020-12-11

Advertisement

More documents for Atriva Therapeutics GmbH

• [1] Atriva Therapeutics GmbH. (4/21/21). "Press Release: Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding". Tübingen....
• [2] Atriva Therapeutics GmbH. (10/20/20). "Press Release: Germany – EIB Backs Atriva Therapeutics with €24 Million for the Development of a Potential COVID-19 Treatment". Germany....
• [3] Atriva Therapeutics GmbH. (8/11/20). "Press Release: Atriva Announces Closing of € 8.6 Million ($ 10.2 Million) Oversubscribed Convertible Loan". Tübingen....
• [4] Atriva Therapeutics GmbH. (2/7/17). "Press Release: Atriva Receives Seed Financing to Develop Its Next Generation Influenza Therapeutic". Tübingen....
• [5] Atriva Therapeutics GmbH. (2/7/17). "Press Release: Atriva Reaches a Development Milestone and Receives an Additional Tranche of Running Seed Financing to Develop Its Influenza Therapeutic to Clinical Stage". Tübingen....
• [6] Atriva Therapeutics GmbH. (11/4/16). "Press Release: Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases". Tübingen....
• [7] Atriva Therapeutics GmbH. (6/30/16). "Press Release: Atriva Therapeutics Completes Transfer of Co-Infection Patent". Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.